Tests a single pill combining empagliflozin, linagliptin and metformin for type 2 diabetes
Tests one pill with empagliflozin, linagliptin and metformin in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
Key facts
- Where
- Faisalabad and Lahore, PakistanSee the 2 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06862739, who can take part
Where in Pakistan
- Faisalabad clinicsFaisalabad, PakistanTaking people
- Aap ka ClinicLahore, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nabiqasim Industries (Pvt) Ltd
- Trial code
- NCT06862739
- Record updated
- 17 April 2026
- Original description
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.Read full original descriptionShow less
Glycemic Control With Triple Pathway Approach Through Empagliflozin-Linagliptin-Metformin
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
Inclusion: Patients of any gender; Patients aged between 18-80 years; Patients having HbA1c 8 % or above; Patients diagnosed with type II diabetes (more than at least 06 months); Patients already on at least 02 or more anti-diabetic agents; Patients not allergic to empagliflozin, linagliptin, or metformin.
Exclusion: Patients with Type-I diabetes; Patients having diabetes for less than 06 months; Patients with decompensated chronic liver disease (DCLD); Patients with end-stage heart failure (NYHA Class 4); Patients who are allergic to empagliflozin, linagliptin, or metformin; Patients with eGFR less than 30 ml; Patients with age less than 18; Patients on GLP-1 and GIP; Patients who are pregnant or lactating females; Patients who are not willing to consent; Patients who are unable to give medical history.